Gapping up
In reaction to earnings/guidance:
- SCS +5.2%, ACN +4.4%, GMS +2.2%
Other news:
- ARAV +23.1% (announces "positive" initial results from the Phase 1b portion of its Phase 1b/2 study in patients dosed with 15mg/kg of AVB-500 in combination with cabozantinib who have clear cell renal cell carcinoma)
- DHX +19% (announces additional $12 mln authorization under share buyback program)
- RCUS +18.6% (Phase 2 ARC-7 study with domvanalimab-based combinations showed encouraging clinical activity)
- KUKE +8.8% (Kuke Music Holding's KUKEY Lessons have been included in China's pre-school music education curriculum and deployed in more than 4,000 kindergartens across China)
- LLY +7.3% (donanemab receives FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease)
- ARAY +6.8% (Family pet's lung cancer is treated with targeted radiotherapy using the Accuray Radixact System with Synchrony Technology; Mac, a Fox Terrier Mix, is doing well following radiotherapy treatment)
- AGTC +5.8% (reports 12-month data from its ongoing phase 1/2 achromatopsia clinical trials showing biologic activity in patients with mutations in the ACHM B3 Gene)
- FSP +5.3% (authorizes the repurchase of up to $50 mln)
- BOCH +4.6% (Bank of Commerce to merge into Columbia Banking System (COLB) in all-stock transaction)
- KPTI +4.5% (expands royalty agreement with HealthCare Royalty Management for up to $100 mln)
- FSLR +4.2% (US to block some solar goods made in Xinjiang region, according to Bloomberg)
- KOR +3.7% (received additional drill hole results from the Mother Lode mineral resource expansion program)
- KZIA +3.3% (granted patents by the respective agencies of the United States and India in respect of the manufacturing process for paxalisib)
- IPI +3.2% (announces increase to potash and Trio pricing)
- ZEAL +2.9% (announced that ZEGALOGUE (dasiglucagon) injection 0.6mg/0.6mL is now commercially available in the U.S. in both an auto-injector and prefilled syringe) LODE +2.2% (to purchase an additional 5% of its 45%-owned technology development partner Quantum Generative Materials in exchange for $50 million)
- VKTX +2% (announces the initiation of a Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta, in patients with X-linked adrenoleukodystrophy)
- PACB +1.3% (announces collaboration for whole genome sequencing)
- ALNY +1.3% (announces FDA acceptance of new drug application for investigational vutrisiran for the treatment of the polyneuropathy of hereditary ATTR amyloidosis)
- MPW +1.1% (MPW to acquire five hospitals from THC for $900 mln)
- VRAY +1% (GenesisCare expanded its partnership with ViewRay)
Analyst comments:
- MGA +3% (upgraded to Buy from Neutral at Goldman)
- LEA +2.6% (upgraded to Buy from Neutral at Goldman)
- CS +2.5% (upgraded to Buy from Hold at Berenberg)
- MGM +2.5% (upgraded to Buy from Hold at Deutsche Bank)
- APTV +1.8% (upgraded to Buy from Neutral at Guggenheim)
- STX +1.5% (upgraded to Outperform from Market Perform at Northland Capital)